WO2023073084A1 - Anticorps d'activation de butyrophiline (btn) 3a à utiliser dans des méthodes de traitement de troubles infectieux - Google Patents

Anticorps d'activation de butyrophiline (btn) 3a à utiliser dans des méthodes de traitement de troubles infectieux Download PDF

Info

Publication number
WO2023073084A1
WO2023073084A1 PCT/EP2022/080048 EP2022080048W WO2023073084A1 WO 2023073084 A1 WO2023073084 A1 WO 2023073084A1 EP 2022080048 W EP2022080048 W EP 2022080048W WO 2023073084 A1 WO2023073084 A1 WO 2023073084A1
Authority
WO
WIPO (PCT)
Prior art keywords
btn3a
antibody
cells
activating
seq
Prior art date
Application number
PCT/EP2022/080048
Other languages
English (en)
Inventor
Daniel Olive
Soraya MEZOUAR
Jean-Louis Mege
Paul Frohna
Alemseged Truneh
Laetitia GAY
Original Assignee
Imcheck Therapeutics
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université D'aix-Marseille
Centre National De La Recherche Scientifique
Institut Jean Paoli & Irene Calmettes
Assistance Publique Hopitaux De Marseille
Institut De Recherche Pour Le Développement (Ird)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcheck Therapeutics, INSERM (Institut National de la Santé et de la Recherche Médicale), Université D'aix-Marseille, Centre National De La Recherche Scientifique, Institut Jean Paoli & Irene Calmettes, Assistance Publique Hopitaux De Marseille, Institut De Recherche Pour Le Développement (Ird) filed Critical Imcheck Therapeutics
Priority to IL312118A priority Critical patent/IL312118A/en
Priority to CA3234598A priority patent/CA3234598A1/fr
Priority to AU2022378932A priority patent/AU2022378932A1/en
Publication of WO2023073084A1 publication Critical patent/WO2023073084A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Definitions

  • BTN3A has its general meaning in the art. In specific embodiments, it refers to human BTN3A polypeptides including either BTN3A1 of SEQ ID NO:32, BTN3A2 of SEQ ID NO:33 or BTN3A3 of SEQ ID NO:34.
  • the fourth proposal was to use the donor amino acid reside at the framework positions at which the amino acid is predicted to have a side chain atom within 3A of the CDRs in a three-dimensional model of the antibody and is predicted to be capable of interacting with the CDRs.
  • the above methods are merely illustrative of some of the methods that one skilled in the art could employ to make humanized antibodies.
  • One of ordinary skill in the art will be familiar with other methods for antibody humanization.
  • some, most or all of the amino acids outside the CDR regions can be replaced with amino acids from human immunoglobulin molecules but where some, most or all amino acids within one or more CDR regions are unchanged.
  • identity refers to the amino acid sequence identity between two molecules. When an amino acid position in both molecules is occupied by the same amino acid, then the molecules are identical at that position.
  • the identity between two polypeptides is a direct function of the number of identical positions. In general, the sequences are aligned so that the highest order match is obtained (including gaps if necessary).
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.
  • amino acid substitutions relative to the reference polypeptide such as CDR regions it is preferable for amino acid substitutions relative to the reference polypeptide such as CDR regions to be conservative amino acid substitutions.
  • conservative amino acid substitution means a given amino acid can be replaced by a residue having similar physiochemical characteristics, e.g., substituting one aliphatic residue for another (such as lie, Vai, Leu, or Ala for one another), or substitution of one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gin and Asn).
  • conservative substitutions e.g., substitutions of entire regions having similar hydrophobicity characteristics, are known.
  • a BTN3A activating antibody for use of the present disclosure is an antibody fragment of the specific antibodies as disclosed below.
  • Antibody fragments include for example, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, Unibody, and scFv fragments, diabodies, single domain or nanobodies and other fragments.
  • it is a monovalent antibody, such as a Fab of scFv fragments.
  • it is a monovalent BTN3A activating antibody such as a Fab fragment having all 6 CDRs of mAb 103.2.
  • a functional variant antibody of the disclosure is a BTN3A activating fragment of mAb 103.2, such as Fab fragment having variable region heavy and light chain amino acid sequences, or all 6 CDR regions amino acid sequences that are homologous or more specifically identical to the corresponding amino acid sequences of any the reference antibody mAb 103.2 or a humanized form thereof, described above, and wherein such functional variant antibodies retain the desired functional properties of said reference antibody.
  • BTN3KO cells transfected with human BTN3A1 can be stained with saturing concentration (e.g.,10 pg/mL) of the reference antibody mAb 3.
  • saturing concentration e.g. 10 pg/mL
  • Different doses of a test BTN3A1 mAbs can then be tested for their competitive potential with the mAb 3 reference antibody.
  • the mAbs that do compete with the reference antibody will not be able to recognize BTN3A1 in the presence of such reference antibody.
  • the antibody for use of the disclosure is a humanized monoclonal antibody of the parent murine antibody mAb 20.1 , including at least the following amino acid mutations in the VH framework regions (as compared to VH parental framework regions): V5Q; V11L; K12V; V20L; R66K; M69L; T75S; M80I; E81Q; R83T; T87S; L108A', and at least the following amino acid mutations in the VK framework regions (as compared to VK framework regions): T5N; V15L ; R18T; V19I ; K39R; K42N ; A43I ; D70G ; F73L ; V104L.
  • polyethylene glycol is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (01-010) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide.
  • the antibody to be pegylated is an aglycosylated antibody. Methods for pegylating proteins are known in the art and can be applied to the antibodies of the disclosure. See for example, EP 0 154 316 by Nishimura et al. and EP 0 401 384 by Ishikawa et al.
  • Regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus (e.g., the adenovirus major late promoter (AdMLP)), and polyoma.
  • CMV cytomegalovirus
  • SV40 Simian Virus 40
  • AdMLP adenovirus major late promoter
  • polyoma e.g., the adenovirus major late promoter (AdMLP)
  • nonviral regulatory sequences may be used, such as the ubiquitin promoter or P-globin promoter.
  • regulatory elements composed of sequences from different sources such as the SRa promoter system, which contains sequences from the SV40 early promoter and the long terminal repeat of human T cell leukemia virus type 1 (Takebe et al., 1988).
  • cytokines examples include cytokines for expanding and/or activating Vy9V52T cells in vivo, including without limitation interleukin 2 (IL-2) (Choudhry H et al, 2018, Biomed Res Int. 2018 May 6), interleukin 15 (IL-15) (Patidar M et al., Cytokine Growth Factor Rev. 2016 Oct;31 :49-59), or their derivatives.
  • IL-2 interleukin 2
  • IL-15 interleukin 15
  • derivative is used for any cytokine modifications that can rely on PEGylation (e.g.
  • IL-15 has its general meaning and refers to the human interleukin-15. Like IL-2, IL- 15 binds to and signals through a complex composed of I L-2/I L-15 receptor beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 regulates the activation and proliferation of T and natural killer (NK) cells.
  • I L-2/I L-15 receptor beta chain CD122
  • gamma-C common gamma chain
  • the subject is selected among the subject at high risk of progression to severe COVID-19.
  • Risk factors include without limitation risk factors include (listed alphabetically) age (risk increases with each decade after age 50), cancer, cardiovascular disease, chronic kidney disease, chronic lung disease, diabetes, immunocompromising conditions or receipt of immunosuppressive medications, obesity (body mass index >30), pregnancy, and sickle cell disease.
  • BTN3A activating antibody for use according to any one of #1 - #3, wherein said BTN3A activating antibody binds to BTN3A with a KD of 10nM or less, preferably with a KD of 1 nM or less, as measured by SPR, for example as described in the Examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de traitement de troubles infectieux. En particulier, l'invention concerne des anticorps d'activation de BTN3A, et leur utilisation dans le traitement de troubles infectieux chez un sujet humain en ayant besoin, tels que des troubles provoqués par une infection à SARS-Cov2 ou à Coxiella burnetii.
PCT/EP2022/080048 2021-10-27 2022-10-27 Anticorps d'activation de butyrophiline (btn) 3a à utiliser dans des méthodes de traitement de troubles infectieux WO2023073084A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL312118A IL312118A (en) 2021-10-27 2022-10-27 Butyrophilin (BTN) A3-activating antibodies for use in infectious disease treatment methods
CA3234598A CA3234598A1 (fr) 2021-10-27 2022-10-27 Anticorps d'activation de butyrophiline (btn) 3a a utiliser dans des methodes de traitement de troubles infectieux
AU2022378932A AU2022378932A1 (en) 2021-10-27 2022-10-27 Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21306505.5 2021-10-27
EP21306505 2021-10-27

Publications (1)

Publication Number Publication Date
WO2023073084A1 true WO2023073084A1 (fr) 2023-05-04

Family

ID=78709378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/080048 WO2023073084A1 (fr) 2021-10-27 2022-10-27 Anticorps d'activation de butyrophiline (btn) 3a à utiliser dans des méthodes de traitement de troubles infectieux

Country Status (4)

Country Link
AU (1) AU2022378932A1 (fr)
CA (1) CA3234598A1 (fr)
IL (1) IL312118A (fr)
WO (1) WO2023073084A1 (fr)

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0154316A2 (fr) 1984-03-06 1985-09-11 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5598369A (en) 1994-06-28 1997-01-28 Advanced Micro Devices, Inc. Flash EEPROM array with floating substrate erase operation
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
WO2012080769A1 (fr) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-cd277 et leurs utilisations
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
WO2020025703A1 (fr) 2018-08-01 2020-02-06 Imcheck Therapeutics Sas Anticorps anti-btn3a et leur utilisation dans le traitement du cancer ou de troubles infectieux
WO2020136218A1 (fr) 2018-12-26 2020-07-02 Imcheck Therapeutics Sas Protéines de liaison btn3a et leurs utilisations

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316A2 (fr) 1984-03-06 1985-09-11 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5598369A (en) 1994-06-28 1997-01-28 Advanced Micro Devices, Inc. Flash EEPROM array with floating substrate erase operation
WO2012080769A1 (fr) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-cd277 et leurs utilisations
WO2012080351A1 (fr) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-cd277 et leurs utilisations
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
WO2020025703A1 (fr) 2018-08-01 2020-02-06 Imcheck Therapeutics Sas Anticorps anti-btn3a et leur utilisation dans le traitement du cancer ou de troubles infectieux
WO2020136218A1 (fr) 2018-12-26 2020-07-02 Imcheck Therapeutics Sas Protéines de liaison btn3a et leurs utilisations

Non-Patent Citations (96)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Immunology", 1992, GREENE PUBLISHING ASSOC. AND WILEY INTERSCIENCE
A. L. LEHNINGER: "Biochemistry", 1975, WORTH PUBLISHERS, pages: 73 - 75
ALEGRE, M.-L.FRAUWIRTH, K.A.THOMPSON, C.B., NAT. REV. IMMUNOL., vol. 1, 2001, pages 220 - 228
ANONYMOUS: "About ICT01: Imcheck Therapeutics", 27 March 2021 (2021-03-27), XP055907804, Retrieved from the Internet <URL:https://web.archive.org/web/20210327234944/https://www.imchecktherapeutics.com/pipeline/ict01/> [retrieved on 20220331] *
APARNA PALAKODETI ET AL: "The Molecular Basis for Modulation of Human Vgamma9Vdelta2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 39, 21 September 2012 (2012-09-21), US, pages 32780 - 32790, XP055562786, ISSN: 0021-9258, DOI: 10.1074/jbc.M112.384354 *
ATSCHUL ET AL., J. MOLECULAR BIOL., vol. 215, 1990, pages 403
BALBI ET AL., AM REV RESPIR DIS, vol. 148, 1993, pages 1685 - 90
BALDWIN, C.L.J.C. TELFER, MOL. IMMUNOL., vol. 66, 2015, pages 35 - 47
BARROSO-SOUSA R ET AL., CURR ONCOL REP, vol. 21, no. 1, 15 November 2018 (2018-11-15), pages 1
BAUDINO, L.SHINOHARA, Y.NIMMERJAHN, F.FURUKAWA, J.-I.NAKATA, M.MARTINEZ-SORIA, E.PETRY, F.RAVETCH, J.V.NISHIMURA, S.-I.IZUI, S., J. IMMUNOL., vol. 181, 2008, pages 6664 - 6669
BENSUSSAN, A.OLIVE, D.: "T-cell: Section report", CELL. IMMUNOL., vol. 236, 2005, pages 3 - 5, XP005197716, DOI: 10.1016/j.cellimm.2005.08.004
BERTOTTO AGERLI RSPINOZZI F ET AL., EUR J IMMUNOL, vol. 23, 1993, pages 1177 - 80
BIRD, R.E.HARDMAN, K.D.JACOBSON, J.W.JOHNSON, S.KAUFMAN, B.M.LEE, S.M.LEE, T.POPE, S.H.RIORDAN, G.S.WHITLOW, M., SCIENCE, vol. 242, 1988, pages 423 - 426
BONNEVILLE MSCOTET E, CURR OPIN IMMUNOL, vol. 18, 2006, pages 539 - 46
BRENNAN, M.DAVISON, P.F.PAULUS, H., SCIENCE, vol. 229, 1985, pages 1202 - 1207
BRYSON, C.J.JONES, T.D.BAKER, M.P., BIODRUGS, vol. 24, 2010, pages 1 - 8
BRYSON, C.J.JONES, T.D.BAKER, M.P.: "Prediction of Immunogenicity of Therapeutic Proteins", BIODRUGS, vol. 24, 2010, pages 1 - 8, XP009178728, DOI: 10.2165/11318560-000000000-00000
C. HARLY ET AL: "Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human T-cell subset", BLOOD, vol. 120, no. 11, 13 September 2012 (2012-09-13), pages 2269 - 2279, XP055081172, ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-430470 *
CACCAMO NLA MENDOLA CORLANDO V ET AL., BLOOD, vol. 118, 2011, pages 129 - 38
CHEN ZW, CELL MOL IMMUNOL, vol. 10, 2013, pages 58 - 64
CHEN ZW, CELL MOL LIFE SCI, vol. 68, 2011, pages 2409 - 1
CHEN ZWLETVIN NL, MICROBES INFECT, vol. 5, 2003, pages 491 - 8
CHEN, S.H. FENGH. XUS. HUANGJ. SUNL. ZHOUJ. HEW. SONGR. WANGX. LI, FRONT. MED., 2020
CHOUDHRY H ET AL., BIOMED RES INT, 6 May 2018 (2018-05-06)
COLLINS, M.LING, V.CARRENO, B.M., GENOME BIOL, vol. 6, 2005, pages 223
CUI ET AL., DRUG DEV IND PHARM, vol. 43, no. 4, 2017, pages 1035 - 1038,1570-1580
DE GASSART AUDE ET AL: "Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vgamma9Vdelta2 T cell-mediated antitumor immune response", SCI. TRANSL. MED, 20 October 2021 (2021-10-20), XP055907566, Retrieved from the Internet <URL:https://www.science.org/doi/epdf/10.1126/scitranslmed.abj0835> [retrieved on 20220331], DOI: 10.1126/scitranslmed.abj0835 *
DEVEREUX ET AL., NUCLEIC ACIDS RES, vol. 12, 1984, pages 387
DIELI FSIRECI GDI SANO C ET AL., MOL MED, vol. 5, 1999, pages 301 - 12
DIELI FTROYE-BLOMBERG MIVANYI J ET AL., J INFECT DIS, vol. 184, 2001, pages 1082 - 5
DONG PJU XYAN Y ET AL., FRONT IMMUNOL, 2018, pages 9
DONG, H.ZHU, G.TAMADA, K.CHEN, L., NAT. MED., vol. 5, 1999, pages 1365 - 1369
DONG, P.X. JUY. YANS. ZHANGM. CAIH. WANGH. CHENY. HUL. CUIJ. ZHANG, FRONT. IMMUNOL., 2018, pages 9
E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17
FREEMAN, G.J.LONG, A.J.IWAI, Y.BOURQUE, K.CHERNOVA, T.NISHIMURA, H.FITZ, L.J.MALENKOVICH, N.OKAZAKI, T.BYRNE, M.C. ET AL., J. EXP. MED., vol. 192, 2000, pages 1027 - 1034
FULLERTON MARISSA S ET AL: "Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells", MSPHERE, 7 July 2021 (2021-07-07), XP055929133, Retrieved from the Internet <URL:https://journals.asm.org/doi/10.1128/mSphere.00442-21> [retrieved on 20220608], DOI: 10.1128/mSphere.00442-21 *
GAY LAETITIA ET AL: "BTN3A Targeting V[gamma]9V[delta]2 T Cells Antimicrobial Activity Against Coxiella burnetii-Infected Cells", FRONTIERS IN IMMUNOLOGY, vol. 13, 27 June 2022 (2022-06-27), XP093019949, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272908/pdf/fimmu-13-915244.pdf> DOI: 10.3389/fimmu.2022.915244 *
GAY LAETITIA ET AL: "V[gamma]9V[delta]2 T cells are potent inhibitors of SARS-CoV-2 replication and exert effector phenotypes in COVID-19 patients", BIORXIV, 19 April 2022 (2022-04-19), XP093019938, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2022.04.15.487518v1> [retrieved on 20230201], DOI: 10.1101/2022.04.15.487518 *
GLENNIE, M.J.MCBRIDE, H.M.WORTH, A.T.STEVENSON, G.T., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375
GOEDDEL, D.V.: "Methods in Enzymology", 1990, ACADEMIC PRESS, article "Systems for heterologous gene expression", pages: 3 - 7
GU, S.NAWROCKA, W.ADAMS, E.J., FRONT. IMMUNOL., 2015, pages 5
HARA TMIZUNO YTAKAKI K ET AL., J CLIN INVEST, vol. 90, 1992, pages 204 - 10
HARLY, C.GUILLAUME, Y.NEDELLEC, S.PEIGNE, C.-M.MONKKONEN, H.MONKKONEN, J.LI, J.KUBALL, J.ADAMS, E.J.NETZER, S. ET AL., BLOOD, vol. 120, 2012, pages 2269 - 2279
HUSTON, J.S.LEVINSON, D.MUDGETT-HUNTER, M.TAI, M.S.NOVOTNY, J.MARGOLIES, M.N.RIDGE, R.J.BRUCCOLERI, R.E.HABER, E.CREA, R., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883
JOUEN-BEADES F ET AL., INFECT IMMUN, vol. 65, 1997, pages 4267 - 72
JUUL SOPHIE ET AL: "Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)", PLOS ONE, vol. 16, no. 3, 11 March 2021 (2021-03-11), pages e0248132, XP055908769, DOI: 10.1371/journal.pone.0248132 *
KARPOVSKY, B.TITUS, J.A.STEPHANY, D.A.SEGAL, D.M., J. EXP. MED., vol. 160, 1984, pages 1686 - 1701
KAUFMAN, R.J.SHARP, P.A., MOL. CELL. BIOL., vol. 2, 1982, pages 1304 - 1319
KLOCKE, K.SAKAGUCHI, S.HOLMDAHL, R.WING, K., PROC. NATL. ACAD. SCI., vol. 113, 2016, pages E2383 - E2392
KROCA MJOHANSSON ASJOSTEDT ATARNVIK A, CLIN DIAGN LAB IMMUNO/, vol. 8, 2001, pages 949 - 54
LATCHMAN, Y.WOOD, C.R.CHERNOVA, T.CHAUDHARY, D.BORDE, M.CHERNOVA, I.IWAI, Y.LONG, A.J.BROWN, J.A.NUNES, R. ET AL., NAT. IMMUNOL., vol. 2, 2001, pages 261 - 268
LEI, L.H. QIANX. YANGX. ZHANGD. ZHANGT. DAIR. GUOL. SHIY. CHENGB. ZHANG, J. CELL. MOL. MED., vol. 24, 2020, pages 11603 - 11606
LINSLEY, P.S.GREENE, J.L.TAN, P.BRADSHAW, J.LEDBETTER, J.A.ANASETTI, C.DAMLE, N.K., J. EXP. MED., vol. 176, 1992, pages 1595 - 1604
LIU, M.A.KRANZ, D.M.KURNICK, J.T.BOYLE, L.A.LEVY, R.EISEN, H.N., PROC. NATL. ACAD. SCI., vol. 82, 1985, pages 8648 - 8652
MARTINO ACASETTI RSACCHI APOCCIA F, J IMMUNOL BALTIM MD, vol. 2007, no. 179, 1950, pages 3057 - 64
MCCAFFERTY, J.GRIFFITHS, A.D.WINTER, G.CHISWELL, D.J., NATURE, vol. 348, 1990, pages 552 - 554
MILLER HALIE K ET AL: "Q Fever: A Troubling Disease and a Challenging Diagnosis", CLINICAL MICROBIOLOGY NEWSLETTER, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 13, 19 June 2021 (2021-06-19), pages 109 - 118, XP086637617, ISSN: 0196-4399, DOI: 10.1016/J.CLINMICNEWS.2021.06.003 *
MORITA ET AL., IMMUNOL REV, vol. 215, 2007, pages 59 - 76
MULLER, METH. ENZYMOL., vol. 92, 1983, pages 589 - 601
NEEDLEMANWUNSCH, J. MOL, BIOL., vol. 48, 1970, pages 444 - 453
NI, L.DONG, C., MOL. CANCER THER., vol. 16, 2017, pages 1203 - 1211
OGANESYAN, V.GAO, C.SHIRINIAN, L.WU, H.DALL'ACQUA, W.F., ACTA CRYSTALLOGR. D BIOL. CRYSTALLOGR., vol. 64, 2008, pages 700 - 704
OLIARO JDUDAL SLIAUTARD JANDRAULT J-BLIAUTARD J-PLAFONT V., J LEUKOC BIOL, vol. 77, 2005, pages 652 - 60
PANOWSKI, S.BHAKTA, S.RAAB, H.POLAKIS, P.JUNUTULA, J.R., MABS, vol. 6, 2013, pages 34 - 45
PATIDAR M ET AL., CYTOKINE GROWTH FACTOR REV, vol. 31, October 2016 (2016-10-01), pages 49 - 59
PAULUS, H., BEHRING INST. MITT., 1985, pages 118 - 132
PERRY, L.C.A.JONES, T.D.BAKER, M.P., DRUGS RD, vol. 9, 2008, pages 385 - 396
POCCIA FAGRATI CMARTINI FCAPOBIANCHI MRWALLACE MMALKOVSKY M, MICROBES INFECT, vol. 7, 2005, pages 518 - 28
POCCIA, F.C. AGRATIC. CASTILLETTIL. BORDIC. GIOIAD. HOREJSHG. IPPOLITOP.K.S. CHAND.S.C. HUIJ.J.Y. SUNG, J. INFECT. DIS., vol. 193, 2006, pages 1244 - 1249
POCCIA, F.C. AGRATIF. MARTINIG. MEJIAM. WALLACEM. MALKOVSKY, IMMUNOL. LETT., vol. 100, 2005, pages 14 - 20
POQUET YKROCA MHALARY F ET AL., INFECT IMMUN, vol. 66, 1998, pages 2107 - 14
QIN, G.H. MAOJ. ZHENGS.F. SIAY. LIUP.-L. CHANK.-T. LAMJ.S.M. PEIRISY.-L. LAUW. TU, J. INFECT. DIS., vol. 200, 2009, pages 858 - 865
REDDY, M.P.KINNEY, C.A.S.CHAIKIN, M.A.PAYNE, A.FISHMAN-LOBELL, J.TSUI, P.MONTE, P.R.D.DOYLE, M.L.BRIGHAM-BURKE, M.R.ANDERSON, D. E, J. IMMUNOL., vol. 164, 2000, pages 1925 - 1933
REMINGTON, J.P.GENNARO, A.R.: "Remington: the science and practice of pharmacy", 1995, MACK PUBLISHING
RHODE PR ET AL., CANCER IMMUNOL RES, vol. 4, no. 1, 2016, pages 49 - 60
RHODES, D.A.STAMMERS, M.MALCHEREK, G.BECK, S.TROWSDALE, J., GENOMICS, vol. 71, 2001, pages 351 - 362
RICH RLDAY YSMORTON TAMYSZKA DG: "High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACOREO", ANAL BIOCHEM, vol. 296, no. 2, 15 September 2001 (2001-09-15), pages 197 - 207, XP002307383, DOI: 10.1006/abio.2001.5314
RIJKERS GER ET AL: "More bricks in the wall against SARS-CoV-2 infection: involvement of [gamma]9[delta]2 T cells", CELLULAR & MOLECULAR IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 17, no. 7, 28 May 2020 (2020-05-28), pages 771 - 772, XP037183153, ISSN: 1672-7681, [retrieved on 20200528], DOI: 10.1038/S41423-020-0473-0 *
RIJKERS, G.T. VERVENNEP. VAN DER POL, CELL. MOL. IMMUNOL., vol. 17, 2020, pages 771 - 772
RUDDY, D.A.KRONMAL, G.S.LEE, V.K.MINTIER, G.A.QUINTANA, L.DOMINGO, R.MEYER, N.C.IRRINKI, A.MCCLELLAND, E.E.FULLAN, A. ET AL., GENOME RES, vol. 7, 1997, pages 441 - 456
RYAN-PAYSEUR BFRENCHER JSHEN LCHEN CYHUANG DCHEN ZW, J IMMUNOL, vol. 189, 2012, pages 1285 - 93
SAVERINO, D.TENCA, C.ZARCONE, D.MERLO, A.MEGIOVANNI, A.M.VALLE, M.T.MANCA, F.GROSSI, C.E.CICCONE, E., J. IMMUNOL., vol. 162, 1999, pages 5784 - 5791
SCHNEIDER THOMAS ET AL: "The Number and Proportion of Vgamma9Vdelta2 T Cells Rise Significantly in the Peripheral Blood of Patients After the Onset of Acute Coxiella burnetii Infection", CLINICAL INFECTIOUS DISEASE, 1 February 1997 (1997-02-01), pages 261 - 264, XP055908783, Retrieved from the Internet <URL:https://academic.oup.com/cid/article/24/2/261/424482> [retrieved on 20220404], DOI: 10.1093/clinids/24.2.261 *
SCHNEIDER TJAHN H-ULIESENFELD O ET AL., CLIN INFECT DIS, vol. 24, 1997, pages 261 - 4
SHARPE, A.H.FREEMAN, G.J., NAT. REV. IMMUNOL., vol. 2, 2002, pages 116 - 126
SHARPE, A.H.PAUKEN, K.E., NAT. REV. IMMUNOL., vol. 18, 2018, pages 153 - 167
SHUKLA, A.A.HUBBARD, B.TRESSEL, T.GUHAN, S.LOW, D., J. CHROMATOGR. B, vol. 848, 2007, pages 28 - 39
SPENCER CTABATE GSAKALA IG ET AL., PLOS PATHOG, vol. 9, 2013, pages e1003119
STECH, M.NIKOLAEVA, O.THORING, L.STOCKLEIN, W.F.M.WUSTENHAGEN, D.A.HUST, M.DUBEL, S.KUBICK, S., SCI. REP., vol. 7, 2017, pages 12030
STROHL, W.R., CURR. OPIN. BIOTECHNOL., vol. 20, 2009, pages 685 - 691
TAKEBE, Y.SEIKI, M.FUJISAWA, J.HOY, P.YOKOTA, K.ARAI, K.YOSHIDA, M.ARAI, N., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472
UNSWORTH NATHAN B ET AL: "Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells", vol. 21, no. 2, 31 January 2014 (2014-01-31), pages 115 - 123, XP009536420, ISSN: 0929-8665, Retrieved from the Internet <URL:https://benthamscience.com/journals/protein-and-peptide-letters/> DOI: 10.2174/0929866521666131223120036 *
URLAUB, G.CHASIN, L.A., PROC. NATL. ACAD. SCI. U. S. A., vol. 77, 1980, pages 4216 - 4220
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WU ET AL., MOL. BIOL., vol. 294, 1999, pages 151
YAZDANIFAR, M.N. MASHKOURA. BERTAINA, CRIT. REV. MICROBIOL., vol. 46, 2020, pages 689 - 702

Also Published As

Publication number Publication date
AU2022378932A1 (en) 2024-05-02
IL312118A (en) 2024-06-01
CA3234598A1 (fr) 2023-05-04

Similar Documents

Publication Publication Date Title
US11608372B2 (en) Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
KR20200061402A (ko) 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
IL259495B1 (en) Antibodies and methods for using them
US20230201346A1 (en) Binding molecules specific for il-21 and uses thereof
AU2016364891A1 (en) Anti-OX40 antibodies and methods of use thereof
KR20180015650A (ko) 항-ox40 항체 및 이의 사용 방법
US11673950B2 (en) ILT7 binding molecules and methods of using the same
KR20140069172A (ko) 항­ｃｄ １３４（ｏｘ４０） 및 이의 용도
TW201605901A (zh) Ｐｄ－１抗體、其抗原結合片段及其醫藥用途
US20240117041A1 (en) Antibodies having specificity for btn2 and uses thereof
CA3152511A1 (fr) Compositions d&#39;anticorps et methodes pour traiter une infection par le virus de l&#39;hepatite b
WO2023073084A1 (fr) Anticorps d&#39;activation de butyrophiline (btn) 3a à utiliser dans des méthodes de traitement de troubles infectieux
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
RU2794996C2 (ru) Антитела, обладающие специфичностью к btn2, и их применение
WO2021175954A1 (fr) Anticorps ayant une spécificité pour btnl8 et leurs utilisations
RU2804456C1 (ru) Связывающие молекулы, специфичные к ил-21, и области их применения
WO2023052541A1 (fr) Combinaison d&#39;un anticorps d&#39;activation anti-btn3a et d&#39;un agoniste il-2 en vue d&#39;une utilisation en thérapie
NZ762893B2 (en) Binding molecules specific for il-21 and uses thereof
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22812532

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 3234598

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: AU2022378932

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 312118

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2022378932

Country of ref document: AU

Date of ref document: 20221027

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024008182

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2022812532

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022812532

Country of ref document: EP

Effective date: 20240527